Eris Lifesciences Limited (ERIS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eris Lifesciences Limited (ERIS) has a cash flow conversion efficiency ratio of 0.068x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs2.39 Billion ≈ $25.85 Million USD) by net assets (Rs35.03 Billion ≈ $378.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Eris Lifesciences Limited net asset quality index to measure how much of total assets are equity-financed.
Eris Lifesciences Limited - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Eris Lifesciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ERIS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Eris Lifesciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eris Lifesciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Blackbaud Inc
NASDAQ:BLKB
|
0.682x |
|
Changshu Tianyin Electromechan
SHE:300342
|
0.028x |
|
Polibeli Group Ltd Class A Ordinary Shares
NASDAQ:PLBL
|
0.000x |
|
Huaxia Eye Hospital Group Co. Ltd. A
SHE:301267
|
N/A |
|
CSSC Steel Structure Engineering Co Ltd
SHG:600072
|
-0.046x |
|
Select Medical Holdings
NYSE:SEM
|
-0.002x |
|
Xiangtan Electric Manufacturing Co Ltd
SHG:600416
|
-0.020x |
|
SF Diamond
SHE:300179
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Eris Lifesciences Limited (2012–2025)
The table below shows the annual cash flow conversion efficiency of Eris Lifesciences Limited from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see ERIS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs32.72 Billion ≈ $353.83 Million |
Rs10.65 Billion ≈ $115.18 Million |
0.326x | +115.80% |
| 2024-03-31 | Rs32.22 Billion ≈ $348.45 Million |
Rs4.86 Billion ≈ $52.56 Million |
0.151x | +14.82% |
| 2023-03-31 | Rs22.21 Billion ≈ $240.16 Million |
Rs2.92 Billion ≈ $31.55 Million |
0.131x | -33.73% |
| 2022-03-31 | Rs19.08 Billion ≈ $206.36 Million |
Rs3.78 Billion ≈ $40.91 Million |
0.198x | -16.75% |
| 2021-03-31 | Rs15.76 Billion ≈ $170.48 Million |
Rs3.75 Billion ≈ $40.59 Million |
0.238x | +13.85% |
| 2020-03-31 | Rs12.96 Billion ≈ $140.19 Million |
Rs2.71 Billion ≈ $29.32 Million |
0.209x | +9.62% |
| 2019-03-31 | Rs11.69 Billion ≈ $126.40 Million |
Rs2.23 Billion ≈ $24.12 Million |
0.191x | -27.96% |
| 2018-03-31 | Rs8.86 Billion ≈ $95.81 Million |
Rs2.35 Billion ≈ $25.37 Million |
0.265x | -28.46% |
| 2017-03-31 | Rs5.40 Billion ≈ $58.39 Million |
Rs2.00 Billion ≈ $21.61 Million |
0.370x | -8.77% |
| 2016-03-31 | Rs3.24 Billion ≈ $35.04 Million |
Rs1.31 Billion ≈ $14.22 Million |
0.406x | +21.46% |
| 2015-03-31 | Rs2.70 Billion ≈ $29.16 Million |
Rs900.57 Million ≈ $9.74 Million |
0.334x | -32.59% |
| 2014-03-31 | Rs1.81 Billion ≈ $19.56 Million |
Rs896.24 Million ≈ $9.69 Million |
0.496x | +44.48% |
| 2013-03-31 | Rs1.11 Billion ≈ $11.99 Million |
Rs380.15 Million ≈ $4.11 Million |
0.343x | -40.12% |
| 2012-03-31 | Rs528.98 Million ≈ $5.72 Million |
Rs302.99 Million ≈ $3.28 Million |
0.573x | -- |
About Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women… Read more